Category Archives: healthcare

New Republican Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy

The 2014 mid-term elections handed over control of the Senate to Republicans and boosted the GOP majority in the House, a clear blow to Obama administration policies, including the president’s landmark health reform initiative.  Voters were most dismayed about the economy and lack of jobs, but U.S. military snafus overseas and concerns about the Ebola […]
Also posted in Op-Ed, Regulatory | Tagged , , , , , , | Leave a comment

Legislators Urge Added Incentives for Ebola Drug Development

Leading Senators are proposing legislation to add Ebola to the list of diseases eligible for priority review vouchers from the Food and Drug Administration as an incentive for biopharma companies to invest in treatments for this deadly disease. The priority review voucher (PRV) program for neglected tropical diseases (NTDs) currently applies to 16 deadly conditions […]
Also posted in Regulatory | Tagged , , , , | Leave a comment

US Healthcare Reform: A Pharm Exec Digest Special

This month’s special issue of Pharm Exec Global Digest looks at Dealing with the “side effects” of Obamacare The “value” of Rxs under Obamacare The escalating cost of US oncology care And more… Click here to read the issue.
Also posted in Global, Regulatory | Tagged , , , | Leave a comment

Pulling Back the Curtains on Obamacare Rx Usage

It’s fall and the 2015 Obamacare Exchange Rx insurance offerings will be presented to patients on November 15th. But at this point, what insights do American Rx brand managers and marketers actually have on the results of the Obamacare Rx experience in 2014? Up until now, very little publicly available information on what Obamacare Rx […]
Also posted in Op-Ed | 1 Comment

Cancer Medicines: Setbacks and Stepping Stones

A report released on this week by the Pharmaceutical Research and Manufacturers of America (PhRMA), “Researching Cancer Medicines: Setbacks and Stepping Stones,” highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called “failures” are a crucial part of the drug development process.
Also posted in R&D | Tagged , , , , | 1 Comment
  • Categories

  • Meta